title: [A randomized controlled study of chemotherapy: etoposide combined with oxaliplatin or cisplatin regimens in the treatment of extensive-stage small cell lung cancer in elderly patients].
abstract: BACKGROUND
  Etoposide combined cisplatin (EP) is the most commonly-used first-line treatment combination chemotherapy regimen in the treatment of extensive-stage small cell lung cancer (SCLC), The side-effects of cisplatin, such as nausea and vomiting, influence patients' quality of life. This study aims to compare the efficacy and toxicities between etoposide plus oxaliplatin (EO) and etoposide plus cisplatin (EP) regimens as first-line chemotherapy for elderly patients with SCLC.
  
  
  METHODS
  Seventy-one old, extensive-stage SCLC patients, who had not received anti-tumor treatment, were randomly divided into two groups, namely, EO group (etoposide: 80 mg/m² d1-5+oxaliplatin; 130 mg/m² d1; repeated every 21 days) and EP group (etoposide: 80 mg/m²  d1-5+cisplatin; 25 mg/m² d1-3; repeated every 21 days). Efficacy and toxicities were evaluated after 2 or more cycles.
  
  
  RESULTS
  No statistical differences were observed between the EO and EP groups in the response rate (55.9% vs 54.3%, P=0.894), disease control rate (82.4% vs 77.1%, P=0.591), median progression free survival (5.5 months vs 4.7 months, P=0.638), and median survival time (10.5 months vs 9.1 months, P=0.862). In terms of toxicities, the incidence of nausea/vomiting in the EO group was significantly lower than that in the EP group (65.7% vs 97.2%, P=0.001), but the neurotoxicity of grade 1-2 in the EO group was more significant (74.3% vs 11.1%, P<0.001).
  
  
  CONCLUSIONS
  The clinical efficiency of EO and EP regimens is similar to the first-line chemotherapy for extensive-stage SCLC in elderly patients. However, the tolerance of EO regimens is better than that in the EP regiments.
authors: Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Dan
authors: D
authors: Pu
authors: Mei
authors: M
authors: Hou
authors: Zhixi
authors: Z
authors: Li
authors: Xiaomei
authors: X
authors: Zeng
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077150:Oxaliplatin; D012449:Safety; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005047:Etoposide; D002945:Cisplatin